Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN BRCA/ATM: Avelumab + Talazoparib in Solid Tumors
NCT03565991Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2018
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of avelumab, talazoparib in solid tumor, sponsored by Pfizer. Started Jun 2018; status: terminated.
02
Drugs
avelumabtalazoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03565991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565991.